Abstract:ABSTRACT Flavivirus infection capitalizes on cellular lipid metabolism to remodel the cellular intima, creating a specialized lipid environment conducive to viral replication, assembly, and release. The Japanese encephalitis virus (JEV), a member of the Flavivirus genus, is responsible for significant morbidity and mortality in both humans and animals. Currently, there are no effective antiviral drugs available to combat JEV infection. In this study, we embarked on a quest to identify anti-JEV compounds within a lipid compound library. Our research led to the discovery of two novel compounds, isobavachalcone (IBC) and corosolic acid (CA), which exhibit dose-dependent inhibition of JEV proliferation. Time-of-addition assays indicated that IBC and CA predominantly target the late stage of the viral replication cycle. Mechanistically, JEV nonstructural proteins 1 and 2A (NS1 and NS2A) impede 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation by obstructing the liver kinase B1 (LKB1)–AMPK interaction, resulting in decreased p-AMPK expression and a consequent upsurge in lipid synthesis. In contrast, IBC and CA may stimulate AMPK by binding to its active allosteric site, thereby inhibiting lipid synthesis essential for JEV replication and ultimately curtailing viral infection. Most importantly, in vivo experiments demonstrated that IBC and CA protected mice from JEV-induced mortality, significantly reducing viral loads in the brain and mitigating histopathological alterations. Overall, IBC and CA demonstrate significant potential as effective anti-JEV agents by precisely targeting AMPK-associated signaling pathways. These findings open new therapeutic avenues for addressing infections caused by Flaviviruses. IMPORTANCE This study is the inaugural utilization of a lipid compound library in antiviral drug screening. Two lipid compounds, isobavachalcone (IBC) and corosolic acid (CA), emerged from the screening, exhibiting substantial inhibitory effects on the Japanese encephalitis virus (JEV) proliferation in vitro . In vivo experiments underscored their efficacy, with IBC and CA reducing viral loads in the brain and mitigating JEV-induced histopathological changes, effectively shielding mice from fatal JEV infection. Intriguingly, IBC and CA may activate 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) by binding to its active site, curtailing the synthesis of lipid substances, and thus suppressing JEV proliferation. This indicates AMPK as a potential antiviral target. Remarkably, IBC and CA demonstrated suppression of multiple viruses, including Flaviviruses (JEV and Zika virus), porcine herpesvirus (pseudorabies virus), and coronaviruses (porcine deltacoronavirus and porcine epidemic diarrhea virus), suggesting their potential as broad-spectrum antiviral agents. These findings shed new light on the potential applications of these compounds in antiviral research.

Effective Inhibition of Japanese Encephalitis Virus Replication by Shrnas Targeting Various Viral Genes in Vitro and in Vivo.

Lentiviral Vector-Derived Shrnas Confer Enhanced Suppression of Semliki Forest Virus Replication in Bhk-21 Cells Compared to Shrnas Expressed from Plasmids

Novel antiviral discoveries for Japanese encephalitis virus infections through reporter virus‐based high‐throughput screening

Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening

Cellular Interleukin Enhancer-Binding Factor 2, ILF2, Inhibits Japanese Encephalitis Virus Replication In Vitro

Inhibition of human IFN-α on Japanese encephalitis virus replication in BHK-21 cells

SLC25A12 inhibits Japanese encephalitis virus replication by interacting with the NS1 and enhancing the type I interferon response

Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies

Screening a neurotransmitter-receptor-related inhibitor library identifies clomipramine HCl as a potential antiviral compound against Japanese encephalitis virus

Antiviral activity of prion protein against Japanese encephalitis virus infection in vitro and in vivo

Natural products and derivatives as Japanese encephalitis virus antivirals

Marine Brown Algae-Derived Compounds as Potential Inhibitors of Japanese Encephalitis Virus RNA-Dependent RNA Polymerase

Microrna Transcriptome Profiling of Mice Brains Infected with Japanese Encephalitis Virus by Rna Sequencing

Japanese encephalitis virus restricts HMGB1 expression to maintain MAPK pathway activation for viral replication

Engineered External Guide Sequences Effectively Block Viral Gene Expression and Replication in Cultured Cells

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

Current Advances in Japanese Encephalitis Virus Drug Development

Japanese Encephalitis Virus NS1′ Protein Interacts with Host CDK1 Protein to Regulate Antiviral Response

Degradation of MicroRNA Mir-466D-3p by Japanese Encephalitis Virus NS3 Facilitates Viral Replication and Interleukin-1β Expression

Two novel compounds inhibit Flavivirus infection in vitro and in vivo by targeting lipid metabolism

Japanese encephalitis virus JEV replicon vector and application thereof